Adherence to Anti–Tumor Necrosis Factor Therapy Administered Subcutaneously and Associated Factors in Patients With Rheumatoid Arthritis

Salaffi, Fausto; Carotti, Marina; Carlo, Marco Di; Farah, Sonia; Gutiérrez, Marwin

doi:10.1097/rhu.0000000000000320

Cited by 32 publications

(38 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Persistence on treatment has been identified as a surrogate for treatment effectiveness; however, in the absence of patient level data in our study, it is not possible to determine whether these results are consistent with the published data reflecting real‐world efficacy or representative of the underlying characteristics of specific patient populations receiving specific treatments as restricted under the Australian funding rules for bDMARDs…”

Section: Discussioncontrasting

confidence: 58%

See 1 more Smart Citation

A retrospective review of the persistence on bDMARDs prescribed for the treatment of rheumatoid arthritis in the Australian population

et al. 2017

View full text Add to dashboard Cite

show abstract

Section: Discussioncontrasting

confidence: 58%

“…Persistence on treatment has been suggested as a surrogate for treatment effectiveness . There is limited data on treatment persistence by mode of action in the same RA population.…”

Section: Introductionmentioning

confidence: 99%

A retrospective review of the persistence on bDMARDs prescribed for the treatment of rheumatoid arthritis in the Australian population

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Some studies 3 , 15 – 17 suggested that higher medication adherence with RA exhibits achievement of lower disease activity during treatment with drugs. However, these results were challenged and not confirmed by other studies, 18 – 20 and no systematic review was conducted to quantify the association of medication adherence and disease activity in RA using meta-analysis techniques. The objectives of this systematic review were: 1) to find the relationship between medication adherence and disease activity among adult RA patients; 2) to provide a summary of the methods used to define medication adherence and disease activity in RA, and 3) to summarize supportive measures to enhance medication adherence.…”

Section: Introductionmentioning

confidence: 87%

Medication adherence has an impact on disease activity in rheumatoid arthritis: a systematic review and meta-analysis

Li¹,

Cui²,

Yin³

et al. 2017

PPA

View full text Add to dashboard Cite

ObjectiveDisease activity of rheumatoid arthritis (RA) patients was often measured by the 28-joint count disease activity score (DAS-28), which consists of 28 swollen and tender joint counts, patient’s assessment of disease activity (visual analog scale [VAS]) and erythrocyte sedimentation rate. C-reactive protein was also used to measure disease activity in RA patients. The aim was to explore the impact of medication adherence on disease activity in patients with RA.MethodsA systematic search was performed in major electronic databases (PubMed, Web of Science, the Cochrane Library, CNKI, VIP and Wan fang) to identify studies reporting medication adherence and disease activity in RA patients. Results were expressed as mean difference (MD) and 95% CI.ResultsA total of seven identified studies matched the inclusion criteria, reporting on a total of 1,963 adult RA patients in the analysis. The total score of DAS-28 was significantly lower in adherent patients than in nonadherent subjects (MD =−0.42, 95% CI [−0.80, −0.03], P=0.03). Similarly, a significant difference was observed between medication adherent and nonadherent groups in erythrocyte sedimentation rate (MD =−7.39, 95% CI [−11.69, −3.08], P<0.01) and tender joint count (MD =−1.29, 95% CI [−2.51, −0.06], P=0.04). Interestingly, the results of the meta-analysis showed no significant difference between medication adherent and nonadherent patients in swollen joint count (MD =−0.16, 95% CI [−2.13, 1.80], P=0.87), visual analog scale (MD =1.41, 95% CI [−3.68, 6.50], P=0.59) and C-reactive protein (MD =0.35, 95% CI [−0.64, 1.34], P=0.49).ConclusionThe study suggests that RA patients with higher medication adherence tended to have lower disease activity.

show abstract

“…31 With regard to adherence, which is a related but different concept, previous studies suggested a lower adherence among older patients. 41 Both adherence and persistence were reported to be related to treatment satisfaction, 42 which underlines the relevance of defining persistence as a treatment goal in RA.…”

mentioning

confidence: 99%

Persistence with Biologic Agents for the Treatment of Rheumatoid Arthritis in Japan

Mahlich¹,

Sruamsiri²

2016

Value in Health

View full text Add to dashboard Cite

Adherence to Anti–Tumor Necrosis Factor Therapy Administered Subcutaneously and Associated Factors in Patients With Rheumatoid Arthritis

Abstract: The overall nonadherence with subcutaneous biologic therapy is relatively high among RA patients and should be taken into account when a patient's response to treatment is unsatisfactory.

Cited by 32 publications

References 43 publications

A retrospective review of the persistence on bDMARDs prescribed for the treatment of rheumatoid arthritis in the Australian population

A retrospective review of the persistence on bDMARDs prescribed for the treatment of rheumatoid arthritis in the Australian population

Medication adherence has an impact on disease activity in rheumatoid arthritis: a systematic review and meta-analysis

Persistence with Biologic Agents for the Treatment of Rheumatoid Arthritis in Japan

Contact Info

Product

Resources

About